Bonviva Tablets 150mg

Description

Bonviva Tablets 150mg

Product Overview Bonviva Tablets 150mg are a new bisphosphonate medication designed for the treatment and prevention of postmenopausal osteoporosis. It functions as an inhibitor of bone resorption and osteoclast activity, effectively helping to increase and maintain bone mass, thereby reducing the risk of fractures in postmenopausal women.

Indications and Usage Bonviva is used for:

• Treatment of Postmenopausal Osteoporosis: Helps increase bone mineral density and reduce the risk of fractures.
• Prevention of Postmenopausal Osteoporosis: Helps maintain bone mass and prevent fractures.

Unique Dosing Schedule Bonviva Tablets 150mg stand out as the first and only bisphosphonate with a once-monthly dosing schedule. This regimen:

• Enhances patient compliance due to the convenience of taking one pill a month.
• Provides powerful protection against postmenopausal osteoporosis.
• Proven efficacy in reducing fracture risk.

Clinical Efficacy

• Clinical studies involving over 12,000 patients have demonstrated the effectiveness of Bonviva in increasing bone mineral density and preventing fractures.
• Approved by the FDA in March 2005 and the European Union in September 2005.

Structure and Composition Bonviva Tablets come in different formulations, including:

• 150mg Coated Tablets: Typically packaged in 1 or 3 tablets per pack.
  • Each 150mg tablet contains 150 mg of ibandronic acid (as sodium ibandronate monohydrate 168.75 mg).
• 2.5mg Coated Tablets: Packaged in 28 tablets per pack.
  • Each 2.5mg tablet contains 2.5 mg of ibandronic acid (as sodium ibandronate monohydrate 2.813 mg).

Key Benefits

• Monthly Convenience: Only one pill per month increases adherence to therapy.
• Efficacy Against Fractures: Proven reduction in fracture risk in clinical studies.
• Preferred by Patients: Offers the special comfort and convenience preferred by many patients.

Bonviva Tablets 150mg offer a unique, effective, and convenient solution for managing and preventing postmenopausal osteoporosis, ensuring better patient compliance and improved bone health.